In NSCLC, CD74 is the most common fusion partner of the ROS1 gene, accounting for approximately 38% of cases, followed by EZR (13%), SDC4 (13%), and SLC34A2 (10%).7 This evidence concerns the gene SLC34A2 and non-small cell lung carcinoma.